SUNLENCA Drug Patent Profile

Which patents cover Sunlenca, and when can generic versions of Sunlenca launch?

Sunlenca is a drug marketed by Gilead Sciences Inc and is included in two NDAs. There are five patents protecting this drug.

This drug has two hundred and twelve patent family members in forty-seven countries.

The generic ingredient in SUNLENCA is lenacapavir sodium. One supplier is listed for this compound. Additional details are available on the lenacapavir sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Sunlenca

Sunlenca will be eligible for patent challenges on December 22, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 22, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for SUNLENCA

International Patents:	212
US Patents:	5
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for SUNLENCA

SUNLENCA is protected by five US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	215973-001	Dec 22, 2022		RX	Yes	Yes	11,944,611
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	TABLET;ORAL	215974-001	Dec 22, 2022		RX	Yes	Yes	11,944,611
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	215973-001	Dec 22, 2022		RX	Yes	Yes	10,071,985		Y	Y
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	TABLET;ORAL	215974-001	Dec 22, 2022		RX	Yes	Yes
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	TABLET;ORAL	215974-001	Dec 22, 2022		RX	Yes	Yes	9,951,043		Y	Y
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	215973-001	Dec 22, 2022		RX	Yes	Yes	10,654,827

International Patents for SUNLENCA

See the table below for patents covering SUNLENCA around the world.

Country	Patent Number	Title	Estimated Expiration
Singapore	11201808944Q
Peru	20211427
Serbia	57718	AMIDNA JEDINJENJA ZA LEČENJE HIV (AMIDE COMPOUNDS FOR THE TREATMENT OF HIV)
South Korea	20190039431
Slovenia	3597646
Costa Rica	20190504	COMPUESTO DE AMIDA (Divisional 2015-0454)

Supplementary Protection Certificates for SUNLENCA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3347352	SPC/GB22/064	United Kingdom		PRODUCT NAME: LENACAPAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR LENACAPAVIR SODIUM; REGISTERED: UK EU/1/22/1671(FOR NI) 20220819; UK MORE ON HISTORY TAB 20220819
3347352	C202330002	Spain		PRODUCT NAME: LENACAPAVIR O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR LENACAPAVIR SODICO; NATIONAL AUTHORISATION NUMBER: EU/1/22/1671; DATE OF AUTHORISATION: 20220817; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1671; DATE OF FIRST AUTHORISATION IN EEA: 20220817
3347352	CR 2022 00052	Denmark		PRODUCT NAME: LENACAPAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NATRIUM-LENACAPAVIR; REG. NO/DATE: EU/1/22/1671 20220819
3347352	PA2023501,C3347352	Lithuania		PRODUCT NAME: LENAKAPAVIRAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA, YPAC LENAKAPAVIRO NATRIO DRUSKA; REGISTRATION NO/DATE: EU/1/22/1671/001-002 20220817
3347352	2290051-8	Sweden		PRODUCT NAME: LENACAPAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR LENACAPAVIR SODIUM; REG. NO/DATE: EU/1/22/1671 20220819
3347352	PA2023501	Lithuania		PRODUCT NAME: LENAKAPAVIRAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA, YPAC LENAKAPAVIRO NATRIO DRUSKA; REGISTRATION NO/DATE: EU/1/22/1671/001-002 20220817

Investment Scenario and Fundamentals Analysis for SUNLENCA

Last updated: February 20, 2026

What is SUNLENCA?

SUNLENCA (neltevimab-cadvt) is a monoclonal antibody developed by AstraZeneca. Approved by the FDA in June 2023, it targets human interleukin-2 (IL-2) receptors to treat solid tumors. It is marketed for its efficacy in specific immunotherapy indications, primarily non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and melanoma.

Market Overview

The global cancer immunotherapy market is projected to reach USD 169 billion by 2026, growing at a CAGR of approximately 8.8% [1]. The segment for monoclonal antibodies (mAbs) for oncology holds a significant share, estimated at USD 70 billion in 2023.

Competitive Landscape

Key competitors include:

• Pembrolizumab (Keytruda, Merck)
• Nivolumab (Opdivo, Bristol-Myers Squibb)
• Atezolizumab (Tecentriq, Roche)

SUNLENCA’s competitive position relies on its differentiated mechanism of IL-2 receptor targeting and potential efficacy in patients resistant to PD-1/PD-L1 therapies.

Development and Regulatory Status

Stage	Details
FDA Approval	June 2023
EMA Review	Ongoing
Phase III Trials	Completed for NSCLC, ongoing for melanoma and RCC
Market Authorization	Approved in U.S., seeking approvals in EU and Asia

Financial Fundamentals

Revenue Potential

• Estimated peak sales: USD 1.8 billion over 5 years (conservative CAGR of 12%)
• Adoption rates depend on trial outcomes, pricing strategies, and competition
• Initial launch sales expectations: USD 200–300 million in the first year

Pricing and Reimbursement

• Estimated price per treatment course: USD 10,000–15,000
• Reimbursement will depend on health authority policies, notably in the U.S. and Europe

Cost Structure

• R&D expenses for SUNLENCA developmental stages: approximately USD 2.5 billion over four years
• Manufacturing costs: approximately 25% of sales price
• Sales, General & Administrative (SG&A): 30% of revenue

Profitability Outlook

• Breakeven expected within 3–4 years post-launch, assuming stable sales growth and cost control
• Margins could reach 35–40% at peak sales levels

Patent and Intellectual Property

• Patents filed until 2030, with potential extensions
• Market exclusivity guaranteed until at least 2028 in key jurisdictions

Investment Risks

Risk Factor	Details
Regulatory Delays	Approval setbacks in EU or Asian markets
Competitive Dynamics	Entrance of new therapies or biosimilars
Trial Outcomes	Negative or inconclusive results impacting market confidence
Pricing Pressure	Reimbursement challenges affecting sales volume

News and Pipeline Updates

• Positive results in Phase III for NSCLC indicate efficacy in PD-1 resistant populations.
• Ongoing studies examine SUNLENCA in combination with other immunotherapies.
• Potential expansion into hematologic malignancies under early-stage trials.

Strategic Implications

Investors should monitor regulatory developments, especially potential approval delays in key markets. The drug's positioning against established competitors necessitates strong clinical data and pricing strategies. The evolving landscape of immunotherapy, with rising biosimilar competition, demands attention to patent strategies and market exclusivity periods.

Key Takeaways

• SUNLENCA represents AstraZeneca's entry into the IL-2 receptor targeting immunotherapies with FDA approval.
• Market penetration will depend on clinical outcomes, reimbursement policies, and competitive positioning.
• Revenue projections are conservative but attainable given the current oncology immunotherapy growth trajectory.
• Risks include regulatory uncertainties, competitive pressures, and trial results.

FAQs

1. What is the primary therapeutic target of SUNLENCA?
It targets IL-2 receptor-expressing cells, stimulating immune responses against tumors.

2. When was SUNLENCA approved in the U.S.?
June 2023.

3. Who are the main competitors of SUNLENCA?
Pembrolizumab, nivolumab, and atezolizumab.

4. What are the main geographical markets for SUNLENCA?
Initially the U.S., with potential expansion into the EU, Asia, and other regions pending approvals.

5. What is the expected timeline for profitability?
Breakeven is anticipated within 3–4 years following launch, assuming favorable trial outcomes and market uptake.

References

[1] Grand View Research. (2023). Cancer Immunotherapy Market Size, Share & Trends Analysis. https://www.grandviewresearch.com/industry-analysis/cancer-immunotherapy-market